A Self-Assembled Non-Viral vector as Potential Platform for mRNA-Based ... · Potential Platform for mRNA-Based Vaccines Rapid differentiationor maturation and productionof immune
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
IntroductionSeveral studies have demonstrated the immunogenicity oftumors, therefore, cancer cells may potentially be recognizedandattackedby immune system, andmelanoma is oneof thebest-definedimmunogenictumor[1-4].
Essential components of the mammalian immune system arethe antigen presenting cells (APCs), a heterogenous group ofimmune cells specialized to process and presenting antigensfor recognition by certain lymphocytes such as T-cells[5,6].Therefore, they represent a vital component of the innateimmunityandplayapivotalroleinthegenerationandregulationof adaptive immunity by cell-cell interaction (e.g. APC-T-cellinteraction)andreleaseofregulatorycytokines(e.g.IL-12,IL-18andIFN-αor-β)[7,8].ClassicalAPCsincludedendriticcells(DCs),macrophages andB-cells, althoughDCs are themostpowerfulAPC of the mammalian immune system [9]. Represent a keylinkbetween innateandadaptive immunity, given their innateimmunity features. Hence, DCs are an optimal target in thedevelopmentofanti-microbialoranti-cancervaccines.
Essentially, it is possible to resume the innate properties ofDCs in the following sentinel and sensor roles in the immunesystem:(i)Capture,processandpresentGantigens(ii)Migrateintolymphoidorgans,wherenaïveT-cellsareretained,and(iii)
AbstractHere,weshowauniversalanti-cancervaccine,basedonantigen-mRNA-loadedself-assembledpolyplexnanocarrier.Theestablishmentofantigen-specificT-cells,asconsequenceofthevaccination,performedfollowingasubcutaneousrouteofadministration,wasconfirmedbydetectionofIFN-γ/IL-2producingT-cellsinthespleenofthetreatedmice.Moreover,ahighreleaseofTh1-releatedIgGisotypes(IgG2bandIgG2c)wasobserved,indicatingapredominantlyTh1response.Finally,OVA-mRNA-based vaccine formulation has been employed for the treatmentofmelanoma lungmetastasis of B16-OVA challengedmice, inducing amarkedreductionofmetastaticnodulesupto93%.
A Self-Assembled Non-Viral vector as Potential Platform for mRNA-Based Vaccines
Rapiddifferentiationormaturationandproductionof immuneenhancingcytokines,inresponsetoseveralstimulirangingfrominnateimmunityreceptors(e.g.Toll-likereceptors,TLRs)[10,11].Pattern recognition receptors (PRRs) represent the sentinelsof the innate immune system, expressed essentially onto thesurface of dendritic cells and macrophages and they are ableto recognize specific pathogen associated molecular patterns(PAMPs)[12].
ThefamilyofTLRs istheclassofPRRsthat ithasbeenstudiedmostextensivelyandrepresentanimportantgroupofreceptors,as previous studies demonstrated that innate immune systemactivation can be used as vaccine adjuvants to potentiate theadaptive immuneresponseduetheirability toactivatevariousimmune cells simultaneously, through the release of specificcytokines[13,14].
Theuseofnucleicacid-basedvaccines(DNAorRNAencodingforanantigen)isaveryattractivestrategy,ascaninduceefficientlyboth humoral and cellular immune responses, which makestumor escape less likely [15,16]. Additionally, nucleic acid-based vaccine oppositely tomore classic and diffused vaccineformulationcontainingproteinorpeptideantigens,offerseveraladvantages:(i)Unlikepeptide-basedvaccines,theydonotrequirepriorknowledge;(ii)Theyarenotrestrictedbythepatient’sHLAtype; (iii)Finally,nucleicacidscanactasadjuvantbyproviding
2 This article is available in: www.transbiomedicine.com
Despite the promising features of DNA vaccines, in general,theyhavebeenfoundtoelicitarelativelackimmuneresponsecomparetoRNA-basedvaccines[19-22].Thereasonsforthisarenotcompletelyclear,butpossibleexplanationsincludeinefficientdeliveryofDNAintohumancells,duetothefactthatDNAneedsto cross both cell and nuclear membranes to be transcribed,thelowexpressionofDNA-sensingmachinery,andthedifferingexpression of nucleic acid sensing PRRs [17,18]. The relativelypoorimmunogenicityofDNAvaccines,combinedwithconcernsabout their potential for oncogenesis via integration into thehostgenome,hasledtoashiftfromDNAvaccinestowardsRNAvaccines.
In the past, several viral vectors were proposed as DC-transfectionsystemsforthedeliveryofantigen-mRNA,butthesekinds of vectors shown some limitations [23]. First, a poorlyunderstood butwell-documented immunological phenomenoncalled immunodominancemay occur,whereby other antigenicproteins,suchasviralantigens,maskorsuppresstheresponsetothelesspotenttumourantigens[24].Second,activatedCytotoxicT lymphocyte (CTLs)may recognize and kill antigen-presentingDCs, because DCs expressing both viral and tumour antigens,thereforeDCscanbeeliminatedbyvirus-specificTcellsbeforetheycanactivateatumour-specificresponse[25].Ifaviralvectoris used to deliver the tumour antigen, this elimination effectwouldbeamplifiedwithsubsequentimmunizations,asitislikelythatthevirus-specificT-cellpoolwouldbeexpandedwitheachvaccination.Hence,itseemsdesirabletodevelopmethodsofDCtransfection that lead to theexpressionofonly thoseproteinstowardwhichanimmuneresponseisdesired.
Non-viralgenedeliverysystemswere introducedasalternativeto viral-based systems. These vectors have many advantages,suchaseasyoffabricationandlowimmuneresponse[26].Thebiggestdisadvantageofnon-viralvectors inclinicaluse is theirlow in vivo transfectionefficiency.But, contrarily to theclassicgene therapy approaches, for gene-based immunotherapy arelatively low transfection efficiency can be sufficient to elicita strong humoral and cell-mediated antigen-specific immuneresponseandpromotetumorregressionandthegenerationofmemorythatcanpreventrelapse.
cell/tissue targeting is not requested, because it wasdemonstrated that DC targeting and activation is possible bysimple systemic delivery of the mRNA-loaded carrier, withoutthe need for ligand functionalization [27]. Recently, non-viralvectorshavebeenwidelyexploredasvehiclesformRNAdeliveryin the area of mRNA-based immunotherapy, but their clinicalapplicationislimited,becauseusually,anelevateddoseofmRNAisneededforantigen-specificimmunization[27-30].
block copolymer/ PAsp (DET) (poly{N’-[N-(2-aminoethyl)-2-aminoethyl] aspartamide}) homopolymer polyplex as efficientplatform for mRNA-based vaccine (Figure 1A). Although thispolymer has been widely explored as an alternative for genedelivery vector, it hasneverbeenusedasplatform fornucleicacid-based vaccination. The ability of the proposed system toinduce a specific immunization was confirmed employing anmRNAencodingforOvalbumin(OVA)chickenprotein,anantigencommonlyusedasamodelproteinforstudyingantigen-specificimmuneresponses inmice. Interestingly,weshowourvaccineformulation has an intrinsic self-adjuvant propriety given itsabilityto lead, inthetransfectedDCs,arobustreleaseof IL-12and IFN-β,whichare recognizedasapotent vaccineadjuvant,by TLR 7/8 pathway activation. Moreover, OVA-mRNA-loadednanovectorwasabletoinduceahighcell-mediatedandhumoralantigen-specificimmuneresponse.
Finally,amurineOVA-B16lungmetastaticmelanomamodelwasemployed to investigate the anti-tumor effect of the antigen-mRNA loaded polyplex vaccine. Immunization of B16-OVA-bearing mice with OVA-mRNA loaded Polyplex significantlyreducedupto93%thenumberoflungmetastases.
Material and MethodsPolyplex (PAsp (DET)/mRNA) and PEG-Polyplex (PEG-PAsp (DET)/PAsp (DET)/ mRNA) preparation and characterizationPEG-PAsp(DET) block polymer, MW of PEG~12,000 Da, DP ofPAsp(DET)~70andPAsp(DET)homopolymerwithDPofca.50,were purchased from NOFAmerica corporation. One volumeof PAsp(DET) and/or PEG-PAsp(DET) solution (PAsp(DET)/PEG-PAsp(DET)moleratioof100:1and50:1,forPEG-polyplexAandBrespectively)wasmixedwithtwovolumeofmRNAsolutionin10mMTris-HClbuffer (pH7.4) toafinalvolumeof90µl.ThePolyplexeswerepreparedusingdifferentN/Pratio(aminegrouponPAsp(DET)andphosphategroupsonRNA).Afterincubationat roomtemperature for30minutes, thecomplexesarereadytouse.ThesizedistributionandzetapotentialweremeasuredusingaMalvernZetasizerNanoZSdynamiclightscattering(DLS)instrument (Malvern Instruments, Worcestershire, UK). ThemRNA (1 mg/mL) was purchased from Trilink Biotechnologies(SanDiego,CA).
Gel retardation assayPolyplexes and PEG-Polyplexes (250 ng of eGFP-mRNA) wereloadedwith1xRNA loadingbuffer (BioRad,Hercules,CA)andrunona0.7%agarosegel in standard1 x TBEbuffer (BioRad,Hercules,CA)at75mVfor1hour.TheRNAbandswerestainedwithGelRed nucleic acid gel stain (Biotium,Hayward, CA) andthendetectedbyaGelDocsystem(BioRad,Hercules,CA).
Atomic Force Microscopy (AFM)Siliconsubstratewastreatedwithpiranhasolution(H2SO4/H2O2,1:2(vol/vol))for1hourat80°Candwashedwithdistilledwaterthoroughlyandblow-dry.Then,thesubstratewasfunctionalized
with 2-(carbomethoxy) ethyltrimethoxysilane (CETES). Briefly,the silane was diluted to a final concentration of 2% in 95%IsopropylAlcohol(IPA)(madefreshlybyadding5%waterto100%IPA). Then the substratewas submerged in the silane solutionandincubatedundershakinginaThermomixerat1400rpmfor2hoursat35°C.Thesubstratewaswashed3timesRinsewith100%IPAandblow-dry.Then,20µlofdilutedpolyplexessolution(1:100 or 1:200) was dropped onto the silanes-silicon surfaceand incubated for20minutes.After thesurfacewaswashed3times with distilled water and the substrate was immediatelytransferredontotheAFMstagetobeanalyzed.
Stability of polyplexes against heparinPolyplexeswerepreparedandincubatedfor30minwithheparinsolutions of different concentrations, expressed as heparin/mRNA(w/w)ratio(1,2,3,4and5).Thesampleswererunona0.7%agarosegel1xTBEbuffer(BioRad,Hercules,CA)at75mVfor1hour.RNAbandswerestainedwithGelRednucleicacidgelstainandthendetectedbyaGelDocsystem.
Generation of bone marrow derived cells (BMDCs)Dendritic cells from C57BL/6 mice were obtained from bonemarrowaspreviouslydescribed[31].Briefly,BMDCsfromfemurandtibiawereflushedoutusing1%FBS-containingPBSusinga5-mlsyringe.ThecellsweretreatedwithACKlysisbuffer(LonzaInc.) to remove red blood cells and centrifuged at 500 g for 4minutes. The BMDCs were resuspended in RPMI-1640 culturemedium supplemented with 10% FBS (Atlas Biological, FortCollins,CO),0.1%β-mercaptoethanol,1%penicillin/streptomycin(Pen/Strep,10,000unitsofpenicillinand10mgofstreptomycin,Sigma-Aldrich, Saint Louis, MO). The cytokines Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (20 ng ⁄ ml)andIL-4(20ng⁄ml)wereaddedandcellsweresetatadensityof1x106cells ⁄ml.Themediumwaschangedeverytwodaysandnon-adherentcellswereharvestedasimmatureBMDCs.Thecellswereusedforallthetransfectionexperimentsatday5.ThedendriticcellshavebeenroutinelytestedforCD11cexpressionand≥85%ofcellsarepositiveforthismarker.
In vitro transfection using an eGFP-mRNABMDCswere seeded in a 24-well plate at density of 3 x 105inRPMI-1640media supplementedwith 10% fetal bovine serum(FBS, Atlas Biological, Fort Collins, CO), 1% streptomycin/Penicillin (Sigma-Aldrich) and 0.1% β-mercaptoethanol (Sigma-Aldrich). After 24 hours of incubation, the dendritic cellswereincubated for with PEG-Polyplexes prepared using differentN/P ratios (80, 120 and 160) and loaded with 0.5 µg eGFP-mRNA.Fluorescence imageswerecapturedusingafluorescentmicroscopy (Eclipse TE2000-S microscope Nikon Corporation,Tokyo, Japan). Flow cytometry analysis was used to quantifythetransfectionandtranslationefficiencyinBMDCs.CellswereharvestedandresuspendedinPBSwith2%FBSandcytometricanalysis was performed using a BD Accuri C6 flow cytometer(BectonDickinson,BD,FranklinLakes,NJ,USA).Gatesweresettoexcludenecroticcellsandcellulardebrisandthefluorescence
Cytotoxicity test by MTS assayCytotoxicityassayswereperformedusingtetrazoliumcompoundbased CellTiter 96® AQueous One Solution Cell Proliferation(MTS)assay(Promega).Totestforcellularcytotoxicity inducedby polyplexes, the cells were cultured in 96-well plate, withappropriated complete media (Final volume 200 µl) at aconcentration of 104 cells/well. Then, 0.1 µg mRNA loadedpolyplexes were added and MTS assay was then performedaccording to the manufacturer’s instruction at 24 hours aftertreatment.
Cellular uptake mechanismDC2.4cells(ATCC)wereseededin24-wellplatesatadensityof1.5x105cells/mlandincubatedfor24h.Then,theyweretreatedwithPEG-PolyplexespreloadedwitheGFPmRNAafter30minutesof incubation with different inhibitors such as amiloride (0.2mM),chloroquine(100mM),genistein(50µm),chlorpromazine(15 µm) pimozide (10 µm). The cells were washed with ice-coldPBSandthemeanfluorescenceintensitywasobservedbyfluorescent microscopy (Eclipse TE2000-S microscope NikonCorporation,Tokyo,Japan).
Evaluation of dendritic cells maturation markers by flow cytometry analysisDendritic cell activation was achieved by in vitro transfectionusingOVA-mRNA.DC2.4cellswereseededin24-wellplatesatadensityof1.5×105cell/wellin1mlofRPMIcompletemedium(10%FBS,1%Pen/Strep,0.1%β-mercaptoethanol)24hpriortotransfection. Then, PEG-polyplexes containing 0.5 μg ofmRNAwere incubatedwithDC2.4cellsat37°C for24hours.After24hours, the cellswerewashedwithPBSand stained forCD11c,CD40,CD86andMHCII.ThecellswereanalyzedbyBDAccuriC6flowcytometer(BectonDickinson,BD,FranklinLakes,NJ,USA).AlltheantibodiesusedforthisexperimentwerepurchasedfromBDBioscience.
OVA-antigen presentation by dendritic cellsBMDCswere transfectedwith PEG-polyplexes loadedwith 0.5µgofOVA-mRNA,andafter48hoursthecellswerestainedfor10 minutes at room temperature with 25-D1.16 monoclonalantibody(MHCclassIH-2Kb,BDBioscience).Subsequently,thecellswerestained30minuteswithananti-CD11c(BDBioscience)andthenevaluatedusingaBDAccuriC6flowcytometer(BectonDickinson,BD,FranklinLakes,NJ,USA).
MHC I and II–restricted antigen presentation assaysBMDCswereseededataconcentrationof3x105cells/mlina24-wellplateandincubatedfor24hrat37°CinRPMI-1640medium(10%FBS,1%Pen/Strepand0.1%β-mercaptoethanol).Then,atday5ofculture,thedendriticcellsweretransfectedwithPEG-Polyplexesloadedwith0.5µgofOVA-mRNA.After48hours,thetransfected dendritic cells were washed and co-cultured with
4 This article is available in: www.transbiomedicine.com
2017Vol. 8 No. 3: 119
Translational BiomedicineISSN 2172-0479
B3Z, T–T hybridomas against OVA (257–264)/H-2Kb complex,andDOBW,T–ThybridomaagainstOVA(323–339)/I-Adcomplex,T-cellsusingaT-cell/dendriticcellsratioof1:1.T-cellactivationwasmonitored at 24hours bymeasuring IL-2 accumulation inthe supernatant by ELISA (eBioscience). Data shown are fromtriplicateexperiments.
Innate immunity activationDC2.4cellswereculturedin24-wellplatesatadensityof1.5x105 cells in 1ml of completemedium in thepresenceof PEG-Polyplexes loaded with 0.5 µg OVA-mRNA. LPS was used at100ng/mlasapositivecontrol.After24hours incubation, thesupernatantswere collected, then IL-6, TNF-α, IFN-β and IL-12concentrations weremeasured using sandwich ELISA kit (R&DSystems,Minneapolis,MN).
TLR inhibitorsTLR7 (ODN 2087) and TLR7/8 (ODN 20959) inhibitors werepurchased from Militenly Biotec (San Diego, CA). DC2.4 cellswereseededina24-wellplateatadensityof1.5x105in1mlofRPMI-1640completemediumand incubated24hoursat37°C.Then,thedendriticcellswerepre-incubatedfor1hourat37with2.5 µm of TLR inhibitor. Subsequently, PEG-Polyplexes loadedwith0.5µgofOVA-mRNAwereadded intothewellsandafter24hours theculturemediumwascollected tobeanalysed forIL-12 and IFN-β levels by ELISA kit. The dendritic cellswithoutpre-incubationwithTLRinhibitorwereusedaspositivecontrol,whereasthedendriticcellsincubatedinabsenceofOVA-mRNAloaded PEG-Polyplexes with/without inhibitor represent thenegativecontrols.
Mice immunization by two dose injections of OVA-mRNA loaded polyplexesPEG-Polyplex and Polyplex vectors were prepared using anN/P ratio of 120 following the procedure described above.Then, two groups of five BALB/c mice were injected s.c. withpolyplexesandPEG-Polyplexesloadedwith2µgofOVA-mRNA.Aseconds.c.injectionwasperformedafter3daysfromthefirstadministration.ControlmicewereinjectedinthesamemannerwithPBS.Themiceweresacrificed7daysafterthefirstinjectiontoallowspleen, lymphnodes,andbloodcollection.Protaminesulfate/mRNA polyplexes were prepared, mixing protaminesulfate(SigmaAldrich)andOVA-mRNA(TrilinkBiotechnologies)atanw/wratioof2in10mMTris-HClbuffer,pH7.4,followedby20minutesofincubationatroomtemperature.
Ex-vivo detection of antigen-specific T-cells by ELISPOTSpleensandlymphnodeswereharvestedfromimmunizedandcontrol groups of mice. Single-cell suspensions were obtainedand blood cells were lysed using ACK buffer and the cellsuspensions passed through a 70µm cell strainer (BD Falcon).ToquantifytheIFN-γproductionbyex-vivostimulatedantigen-specific T-cells, cells were plated in RPMI-1640 medium at adensityof3x104cells/wellinUNIFILTER®96-wellELISpotplates.Consecutively,cellswerestimulatedwith2ng/mlOVApeptides
(OVA257-264,OT-I,andOVA323-339,OT-II)andOVAprotein.Followingovernightincubation(15–18hr)at37°C,thecellswerewashed3 times with PBS containing 0.05% Tween-20. Plates wereincubated for3 to4hrat roomtemperaturewithbiotinylatedmousesecondaryantibodyforIFN-γ(BioLegend).After3washes,asbefore,theplateswerefurtherincubatedfor2hrwithanti-rabbitIgGHRPO(SIGMA)andthenprocessedforstainingusingan AEC kit according to manufacturer's instructions (VectorLaboratories).Thenumberof spots formingcellswasanalyzedusingImmunoSpotsoftware(CellularTechnology).
Measure ex-vivo IFN-γ release by ELISA assayT-cellswereisolatedfromspleenandlymphnodesaspreviouslydescribed.Thecollectedcellswereculturedin24-wellplatesatadensityof1x106cells/mlandincubatedwith2ng/mlofOVApeptides(OVA257-264specificforMHCclassIandOVA323-339,specificforMHCclassII)andOVAproteinat37°C.After24hincubation,theculturesupernatantwasharvestedandthepresenceofIFN-γwastestedusingacommercialmouseIFN-γimmunoassayELISAkit(BDBioscience)accordingtothemanufacturer'sinstructions.The concentrations of IFN-γ in the samples were determinedfromthestandardcurves.
Measure of OVA-antibodies tittersOVA-specific antibodiestittersweremeasured in the serumofimmunizedmice.Bloodwascollectedby retro-orbitalbleedingon day 14 after immunization, and allowed to clot overnightat4°C.Theserumwasseparatedbycentrifugationat1000xgfor20min. Serumwas collectedandanti-OVAantibodytitterswere determined by enzyme-linked immunosorbent assay, aspreviously described. Briefly, 96-well plates (Nunc-Immuno)werecoatedbyovernightincubationat4°Cwith100μl/wellofPBScontainingOVAat40μg/ml.Plateswereblockedwith1%bovineserumalbumininPBSfor2h,andserialtwofolddilutionsof serum samples in PBSwere added to thewells. After a 2-hincubation,plateswerethenwashedwithPBScontaining0.05%Tween20andincubatedfor1hatroomtemperaturewithHRP-conjugated goat anti-mouse immunoglobulin G (IgG), IgG1,IgG2c,IgG2bandImmunoglobulinM(IgM)antibodies(SouthernBiotechnology Associates). After three additional washes, theplateswerethenincubatedwithtetramethylbenzidinesubstrate.The reaction was stopped by the addition of 1N HCl (Sigma).Absorbancewasreadat450nmwithamicroplatereader(Bio-Rad).AbTiterswerecalculatedastheinversedilutionatwhichthe absorbance equaled that of control mice plus 2 standarddeviations.
In vivo toxicity of PEG-PolyplexCytokineanalysiswasperformedtoassessthecytokineresponseinducing by PEG-Polyplex exposure. A MAP Mouse Cytokine/ChemokineMagneticBeadPanel-Premixed32Plex-ImmunologyMultiplexAssay(EMDMillipore,Darmstadt,Germany)wasusedtomeasurethecytokinelevelssuchasIL-1b,IL-2,IL-6,IL-12(p70),TNF-α,IFN-γ,andRANTES.BALB/cmiceweres.c.injectedwith2µgOVA-mRNAloadedmicellesandafter24hoursserumsampleswereanalyzedinduplicatewellsaccordingtothemanufacture'sinstruction.
In vitro CD8+ T-cell mediated anti-cancer activityDC2.4 cellswere seeded at a density of 1.5 × 105 cells/well in24-wellplatewith1mlofRPMI-1640medium.Afterovernightincubation, dendritic cellswerepre-incubatedwith TLR7 (ODN20958, Miltenyi Biotec, Germany) and TLR7/8 (ODN 2087,Miltenyi Biotec, Germany) inhibitors for 1 hour at 37°C. Then,0.5µgofOVA-mRNAloadedpegylated-polyplexwereaddedandincubatedfor24hoursat37°C.Subsequently,OVA-specificCD8+ T-cells(B3Zcells)wereco-culturedwiththetransfectedDC2.4atT-cell/DC2.4ratioof2:1andincubatedtogetherfor24hoursat37°C.B16-OVAtumorcellswereplatedina96-welltissuecultureplateat0.5×104cellsperwell(200µl)andincubatedovernightat 37°C. The tumor cells were co-cultured with activated B3Zcellsateffector/targetratioof5:1for4,6and24hoursat37°C.Theviabilityof tumorcellswasthendeterminedusinganMTSformazan viability assay (Promega, Madison, WI). The opticaldensityofthewellswasreadat490nmonaplatereader.Themean viability of the treated tumor cells was calculated as apercentagerelativetothecontrolwellswithnon-treatedcancercells(100%survival).Allthesamplesweremeasuredintriplicate.
Metastatic lung cancer modelMicewereinjectedwith2.5×105B16-OVAmelanomatumorcellsintravenouslytoestablishlungmetastases[32].Threedayslater,tumour-bearingmiceweres.c.vaccinatedwith2μgOVA-mRNAloadedmicelles.Micewereboostedatdays7and10.Lungswereharvested18daysfollowingtumorinoculationandfixedwith4%ofparaformaldehyde.Thelungmetastaseswerecountedunderadissectingmicroscope.
TRP2-specific CD8+ T-cells detection in vivoC57BL/6 mice were immunized s.c. with TRP2-mRNA loadedPEG-Polyplexatday3,7and10using thesamedoseofTRP2-mRNA (2μg).Oneweekafter the last immunization thebloodwascollectedandanalyzedbyflowcytometryforthepresenceof tetramer positive CD8+ T-cells (H-2b/TRP2 tetramer, MBL).TetramerpositivecellsareexpressedasthepercentageofCD3+/CD8+Tcells.
Results and DiscussionCharacterization of mRNA-loaded polyplexesSize and zeta potential of the polyplexes were evaluated bydynamic light scattering (DLS) measurements (Figures 1B and 1C), which showed smaller cumulant diameter and a lowerpolydispersity index in thepegylated-polyplexes (PEG-Polyplex)compared with non-pegylated polyplexes (Polyplex). ThepolyplexessizedecreasewithincreasingofN/Pratiointherangefrom10to80,andbeyondthisrangethesizedistributionremainconstant.Butafurthersizereductionwasobservedinresponseto the pegylation and this variation is proportionated to thePEG-PAsp(DET)/PAsp(DET) ratioused forpolyplexpreparation.HigherzetapotentialwasmeasuredwithN/Pratiobetween20-80 and over this range, the superficial charge of the polyplexremainpositivealthough,decreasesignificantly.Moreover,itis
Size and morphology of the non-pegylated and pegylated-polyplexeswere confirmedbyatomic forcemicroscopy (AFM),whichconfirmeda sizedecrease in response to thepegylationand that the size variation is proportioned to the amount ofblock copolymer included in the polyplex formulation (Figures 1D-1F).Whereas, the incorporationofmRNA into thepolyplexwas confirmed by gel retardation assay (Figure 1G). The gelretardation assay revealed completemRNA incorporation intothepolyplexesalreadyemployinganN/Pratioof20(Figure 1G).
Serum and extracellular matrix proteins can lead to vectordisassembly [33]. To evaluate the possible effects of anionicproteins on PEG-Polyplex stability,we tested the susceptibilityof our Nano vector to heparin displacement. Heparin isone of the glycosaminoglycans (GAG), which are negativelychargedpolysaccharidesthatarethemajorcomponentsoftheextracellular matrix in many tissues and it is also present onthecellsurface[34].Polyplexeswereincubatedwithincreasingheparinconcentrations.PolyplexdissociationintermsofmRNArelease was shown by electrophoresis of the samples on angelred-containingagarosegel(Figure 2).Anydissociationdidnotoccurevenathighheparin/mRNA(w/w)ratios.
In vitro optimization of transfection conditionsPrimarycellsareknowntoberesistanttotransfection,therefore,afteroptimizedthepolyplexformulation,wedecidedtoevaluatethetransfectionefficiencyofeGFP-mRNA-loadedpolyplexeswithprimarydendritic cells,which representour target topromotean antigen-specific immune response. BMDCs (Bone marrow-derived cells)were obtained from femurs of BALB/cmice andculturedwithgranulocytemacrophage-colonystimulatingfactor(GM-CSF)andIL-4toinducedendriticcellsdifferentiation.
Thedendriticcellsatdayfiveweretransfectedwithpolyplexesloadedwith0.5µgofeGFP-mRNAand48hourspost-transfectionGFP-positive cells were detected by fluorescence microscopy(Figures 3A-3E).Threedifferentpolyplex formulation,obtainedusinganN/Pratioof80,120and160,weretestedfortransfectionability with dendritic cells. The transfection efficiency wasmeasuredbyFACSanalysisandahighernumberofGFP-positive
cells were observed using an N/P ratio of 120 (Figure 3F).Importantly,MTSassaydidnotdetectanysignificantcytotoxicity,thereforeaspreviouslydemonstratedPAsp(DET)polymerhasanoptimalbiocompatibility(Figure 3G)[35,36].
After having confirmed that polyplexes efficiently deliver themRNA into the DCs, we wanted to elucidate the mechanismbywhichthiscellsuptakemRNA-loadedpolyplexes.Therefore,we examined the different cellular uptake pathways forthe polyplexes using various endocytic inhibitors; each onespecific for a particular endocytic pathway (Figures 3H-3P).The amiloride (blocks macropinocytosis by Na+/H+ exchangerinhibition) significantly decreased the cellular transfectionby 70% (Figure 3P), proving that our polyplexes are able toreleaseefficiently themRNA into the cytosolmainly exploitingmicropinocytosispathway.Aprominentroleofmicropinocytosisin the PEG-Polyplex entry into dendritic cells was confirmedby the substantial reduction (~45%) in transfection efficiencyfollowingpre-treatmentwithcytochalasinDaninhibitorofactinpolymerization(Figure 3P).
Moreover,thisstudyhasrevealedthataddinggenistein(inhibitscaveolin-mediated endocytosis), chlorpromazine (inhibitsclathrin-mediatedendocytosis),Pimozide(inhibitsphagocytosis)did not significantly altered the cellular transfectionefficiency.On the contrary, chloroquine, known to prevent endosomeacidification and maturation, induced a 2-fold improvedtransfection efficiency. Still, it has not been clarified themechanism by which chloroquine increase the transfectionefficiency,butitseemslikelythatendolysosomalaccumulationof
Table 1Averagesizeandpolydispersityindex(PDI)forthesizeintensitydistribution plots shown in Figure 1B. The polyplexeswere preparedusinganeGFP-mRNA(996nt).
HeparindisplacementassayPEG-Polyplexeswere prepared at N/P ratio of 120 andincubatedfor30minat37°Cinthepresenceofincreasingamountsofheparin,expressedasheparin/siRNA(w/w)ratio.
In vitro validation of PEG-Polyplex for mRNA-based vaccine applicationsWith the ability to deliver antigen-mRNA into the cytosol ofdendriticcells,wethendeterminedthatthispropertycouldbecombinedtoelicitdendriticcellsmaturation.Dendriticcellsweretransfectedwith0.5μgofmRNAencodingforOvalbumin(OVA-mRNA),achickenproteinusedasamodelantigenforstudyingantigen-specific immune responses in mice. 48 hours post-treatment dendritic cells displayed a shift from the immatureto the mature phenotype through upregulation of the co-stimulatorymoleculesCD40,CD86,andMHCII(Figure 4A).
MHCclass IImolecules are crucial for the activationof CD4+ Tcells,whichiswellknownfortheircriticalroleintherisingandregulationofadaptiveanti-tumourresponse.Tcellscandirectlymediatecytotoxicityagainsttumorcells.
To test the ability of activated DCs to process antigen thepresence of dendritic cells presenting OVA257– 264 peptide(SIINFEKL)on themajor histocompatibility complex I (MHC-I)was analyzed 48 hours after treatment. The mRNA-basedvaccine was capable of generating a significant number ofSIINFEKL-MHC-I+DCs(Figure 4A).
Primed-T-cells secrete several cytokines, such as interlukin-2(IL-2), which influence various lymphocyte subsets during theimmune responses. For example, IL-2 has a crucial role in themaintenanceofregulatoryT(Treg)cellsandforthedifferentiationofCD4+T cells into specificeffectorT-cell subsets in responseto antigen-mediated activation [37]. Furthermore, IL-2 signalfor CD8+ T-cells regulate both effector T-cell generation anddifferentiationintomemorycells[38].TheelevatedlevelsofIL-2measured in themedium, using an ELISA assay after dendriticcells-T cells co-culture confirm the ability of thedendritic cellstoactivateT-cellsbyMHC-antigenpresentationafterstimulationwith OVA-mRNA-loaded polyplex (Figure 4B). An importantadvantage of mRNA-based immunotherapies over traditionalrecombinant protein vaccines is the ability to activate innate
TransfectionofBMDCswasachievedusingPEG-Polyplexesloadedwith0.5µgofeGFP-mRNAandpreparedemployingdifferentN/P ratio (N/P=80,120and160).Fluorescencemicroscopy imagesshowBMDCs transfectedwith0.5µgofGFP-mRNAloadedPEG-Polyplex(A-E).TheFigureBisthenegativecontrolandFigureC,DandEshowthetransfectionwithPEG-PolyplexobtainedusingN/Pratioof80,120and160respectively..TransfectionefficacyofthePEG-Polyplex,preparedusingaN/Pratioof80,120and160,wasconfirmedandquantifiedusingflowcytometryanalysis(F).ALossinmetabolicactivitywasquantifiedusinganMTSassaywithcolorimetricreadout,measuredbyamultiplatereader(G).Thecytotoxicityassaywasperformedintriplicateforeachsample.EffectoftreatmentwithdifferentendocyticinhibitorsontransfectionefficiencyofeGFP-mRNAloadedPEG-PolyplexbyDC2.4cells.FluorescenceimageofDC2.4cellstransfectedwith PEG-Polyplex loadedwith 0.5μgof eGFP-mRNAand treatedwith different inhibitors (mock, control, amiloride,chlorpromazine,chloroquine,genistein,pimozideandcytocalasinD,figureH, I, J, K, L, M and O respectively).InthefigureP isreportedthe GFPexpressionmediatedbyPEG-Polyplexeswithoutandinthepresenceofendocytosisinhibitors.Thedataisthemeanofthreeindependentexperiments±standarddeviations.
Figure 3
8 This article is available in: www.transbiomedicine.com
immunity by TLR signalling. TLRs were found act as adjuvantreceptors,thatpromoteandpotentiateadaptiveimmunesystembystimulatingthereleaseofseveralcytokines, includingtypeIinterferonandIL-12.TypeIinterferonandIL-12arerecognizedasapowerfuladjuvantthatpotentiatetheantigen-specificimmuneresponse,becausecapableofactivatingT-andNK-cellsforIFN-γproductionandtopromoteCD+Th1immunity[38,39].Immunedeviation towards Th1 responses results in tumor rejection asTh1 pathways typically produce activation of cytotoxic T-celllymphocytes (CTL), natural killer (NK) cells, macrophages andmonocytes, all of which can attack cancer cells and generallydefendagainsttumors.Asignificantup-regulationofIFN-β(1.7fold)andarobustsecretionofIL-12(8fold)wereobservedaftertreatmentofDCswithOVA-mRNA-loadedpolyplexes.Whereas,a non-significant change in the levels of TNF-α and IL-6 wasdetectedinresponsetothetreatmentwithOVA-mRNA-loadedpolyplexes. Interestingly,naked-mRNAandPAsp(DET)polymerwere not able to induce IFN-β and IL-12 release (Figure 4C). TheroleofTLRsinthepromotionofIL-12andTypeIinterferonsecretion, by OVA-mRNA-loaded polyplexes treated DCs, wasprovedusingTLR7(ODN20958)andTLR7/8inhibitors(ODN2087).The release of IL-12 and IFN-β is significantly compromisedbytheinhibitionofTLR7/8pathway(Figures 4D and 4E).Therefore,we can conclude that mRNA-loaded polyplexes induce innateimmunesystemactivationbyTLR7/8signalling.
In vivo antigen-specific immunization by administration of OVA-mRNA loaded PEG-polyplexesToassessthesuccessofin vivoimmunizationinresponsetos.c.injection ofOVA-mRNA-loaded polyplexes,we determined thepresenceofantigen-specificIFN-γsecretingT-cellsinthespleenandlymphnodesoftreatedmice.Themicewereimmunizedbysubcutaneously (s.c.) injection of 2 μgOVA-mRNA, boosted atday3withthesamedoseand,spleensand lymphnodeswereharvested at day 7. The presence of OVA-, OTI-, OTII- specificIFN-γsecretingT-cellswasconfirmedbyELISAandELIspotassays(Figures 5A-5D).High levelsof IFN-γandsignificantnumberofantigen-specificIFN-γsecretingT-cellsweredetectedbothinthespleen(Figures 5A and 5B)andlymphnodesofimmunizedmice,confirming the ability of the proposed vaccine formulation topromoteanantigen-specificadaptiveimmuneresponse.
Induction of OVA-specific immunoglobulin G (IgG, IgG1, IgG2bandIgG2c)andIgMweredetectedintheserumatday7afterfirstOVA-mRNAvaccineadministration(Figures 5E and 5F).Giventhehigh levelsofOVA-specific IgGand IgMdetected in the serumofthevaccinatedmice,wecanaffirmthattheproposedvaccineefficiently induces apotent antigen-specifichumoral response.Moreover, s.c. injection induced high OVA-specific IgG1 andIgG2a titers using only a small amount of OVA-mRNA (2 μg),
With the purpose to demonstrate that the proposed systemsrepresent an important advancement of the current state-of-the-art in the area ofmRNA-base vaccine implementation,wedecidedtocompareourvaccineformulationagainstprotaminesulfate/mRNA polyplex (PS/mRNA), a non-viral vector widelyemployedforantigen-mRNAdeliveryandcurrentlyunderstudyinseveralclinical trials foranti-cancer immunotherapy [40-42].ThedetectionofOVA-specificIFN-γsecretingcellsinthespleenand lymph nodes of vaccinated mice, revealed a significantlyhighernumberofprimedT-cell in themice treatedwithOVA-mRNAloadedPEG-PolyplexthanmicevaccinatedwithPS/OVA-
mRNApolyplex. Contrarily, equivalenttiters of IgG and IgM, itwas found in both vaccination with OVA-mRNA loaded PEG-PolyplexandwithPS/OVA-mRNAcomplex.
A major barrier to the clinical application of nanomaterials istheir potential toxicity. Therefore, we assessed the toxicityassociated with OVA-mRNA-loaded polyplex using wild-typemice. A 32-plex Luminex assay was employed to measurecytokineandchemokineserumlevels,includingIL-1b,IL-2,IL-6,IL-12(p40),IL-12(p70),TNF-α,IFN-γ,RANTES,EotaxinG-CSF,GM-CSF,M-CSF,VEGF,andIP10.AsreportedintheFigures 5G and 5J,24hourspost-treatmentwecanexcludeanypolyplex-relatedpro-inflammatoryortoxicity.
10 This article is available in: www.transbiomedicine.com
2017Vol. 8 No. 3: 119
Translational BiomedicineISSN 2172-0479
Anticancer effect of OVA-mRNA loaded PEG-Polyplex in vitro and in vivoTomeasuretheantigen-specificcell-mediatedimmuneresponsepromoted by immunization with OVA-mRNA-loaded PEG-Polyplexvaccine,weemployedanin vitroCytotoxicTLymphocyte(CTL) cytotoxicity assay. OVA-mRNA transfected DCs were co-incubated with OVA-specific CD8+ T-cells using a ratio of 1:2,then primed-T cellswere co-culturewith B16-OVA tumor cellsat effector/target cells ratio of 5:1. CD8+ T-cell-mediated anti-tumoractivitywasestimatedmeasuringtumorcellviabilityat4,6and24hoursbyMTSassay(Figure 6A).UsingTLR7/8inhibitors,weprovedtheconceptthatinhibitionofthispathway,withtheconsequent block of type-I IFN and IL-12 secretion, affect theanti-tumourcytotoxicimmuneresponse.Indeed,itiswellknown
that IL-12 enhances the function and anti-tumour activity inmurineandhumanCD8+T-cells[43].
Anti-cancermRNA-based immunotherapy is able to induce anantigen-specific cell-mediated and humoral immune responsessufficienttoobtaintumorregression.Toaddressthisquestion,we generated an OVA-B16 melanoma lung metastasis tumormodelandtreateditatday3throughs.c.injectionofOVA-mRNA-loadedpolyplexes,followedbytwoboosterdosesatdays7and10.Themiceweresacrificedatday18post-tumorinoculation.AsshowninFigure 6B,micewithoutvaccination(injectedwithPBS),developedextensivepulmonarymetastases.However,amarkedreductioninpulmonarymetastases(upto93%)wasobservedinmicetreatedwithOVA-mRNA-loadedpolyplexes(Figure 6B).
Tumourcellskillingactivitybyantigen-specificCD8+T-cellswasmonitoredatdifferenttimes(4,6and24hours)byMTSassay(A).ThetumorcellviabilityisreportedasarelativepercentageofB16-OVAcellstreatedwithnon-activatedT-cells.Anti-tumouractivityofOVA-antigenspecificT-cellswasinhibitedby1hourpre-incubationwithTLR7(ODN20958)andTLR7/8 (ODN2087) inhibitors.Thephotographic imagesshowthe lungsharvested fromtumour-bearingmice injectedwith PBS (negative control) andOVA-mRNA loadedPEG-Polyplexes 18 days post-tumor challenge (B). Thehistogramshows thequantificationof B16 lungmetastatic-like tumor foci. Data are presented asmean± standarddeviationofn=5micepergroup.AnalysisoftheTRP2antigen-specificCD8+T-cellfromperipheralbloodofvaccinatedmicebyflowcytometry(C).Mice(n=4pergroup)werevaccinatedwithPBS,TRP2-peptideorTRP2-mRNAloadedPEG-Polyplex.
ConclusionInconclusion,wedemonstrated,thatusingalowdoseofantigen-mRNA, the administration of antigen-mRNA-loaded polyplexescan induce a potent anti-tumor immunity, effective for cancertreatment.Our results contribute to a relatively small numberof studies published on mRNA-loaded nanoparticle mediatingtumor vaccination. In addition, our findings also support theconcept that mRNA-based vaccine offers the advantages topromotesimultaneouslyantigen-specificadaptivecell-mediated,humoral immune response, and it can act as self-adjuvant,promotinginnateimmunitybyTLRs.TLRsignallingpromotesthereleaseofseveralcytokines,suchastypeI interferonandIL-12
that have the capacity to potentiate the anti-tumor adaptiveimmuneresponse.
Self-assembledarefastandinexpensivetoprepareandpotentiallycan be used as a universal platform for anti-tumour mRNA-based immunotherapyapproaches, given that anypolypeptidecan be encoded by mRNA. Thus, the mRNA-loaded polyplexintroducedherecanrepresentanovelandvalidplatformforthedevelopmentofmRNA-basedvaccines.
AcknowledgementThisworkwas fundedby the ItalianFlagshipProjectNanoMax(S.P.)
33 BuyensK,LucasB,RaemdonckK,BraeckmansK,VercammenJ,etal. (2008)A fastandsensitivemethod formeasuring the integrityofsiRNA-carriercomplexes infullhumanserum.JControlRelease126:67–76.
34 Sarrazin S, Lamanna WC, Esko JD (2011) Heparan sulfateproteoglycans.ColdSpringHarbPerspectBiol3:a004952.
35 Itaka K, Ishii T, Hasegawa Y, Kataoka K (2010) Biodegradablepolyaminoacid-basedpolycationsassafeandeffectivegenecarrierminimizingcumulativetoxicity.Biomaterials31:3707-14.
36 AkagiD,ObaM,KoyamaH,NishiyamaN,FukushimaS,etal.(2007)Biocompatiblemicellarnanovectorsachieveefficientgenetransferto vascular lesions without cytotoxicity and thrombus formation.GeneTherapy14:1029-1038.
37 Boyman O, Sprent J (2012) The role of interleukin-2 duringhomeostasisandactivationoftheimmunesystem.NatRevImmunol12:180-190.
38 BlissJ,VanCleaveV,MurrayK,WiencisA,KetchumM,etal.(1996)IL-12, as an adjuvant, promotes a T helper 1 cell, but does notsuppressaThelper2cellrecallresponse.JImmunol156:887-894.